Abe Hisashi, Murakami Takamichi, Kubota Masaru, Kim Tonsok, Hori Masatoshi, Kudo Masayuki, Hashimoto Kazuhiko, Nakamori Shoji, Dono Keizo, Tomoda Kaname, Monden Morito, Nakamura Hironobu
Department of Radiology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 565-0871, Japan.
Radiat Med. 2005 Aug;23(5):364-70.
There has been one report that tissue blood flow (TBF) quantification with xenon CT was effective in predicting the therapeutic response to an anticancer drug in pancreatic cancer. The purpose of this study was to evaluate the correlation between the TBF of pancreatic tumors calculated with xenon CT and those with perfusion CT, in order to evaluate whether perfusion CT could replace xenon CT.
Nine patients with pathologically proved pancreatic tumors who underwent both xenon CT and perfusion CT were included.
Quantitative TBF of pancreatic tumors measured by perfusion CT ranged from 22.1 to 196.2 ml/min/100 g (mean+/-SD, 52.6+/-54.8 ml/min/100 g). In contrast, those obtained by xenon CT ranged from 10.3 to 173.6 ml/min/100 g (mean+/-SD, 47.4+/-49.4 ml/min/100 g). There was a good linear correlation between xenon CT and perfusion CT (y=0.8537x+2.48, R2=0.895: p<0.05).
The TBF of pancreatic tumors measured by xenon CT and perfusion CT techniques showed a close linear correlation. We can expect that perfusion CT based on the deconvolution algorithm may replace xenon CT to predict the effect of pancreatic tumor treatment with anticancer drugs.
有一份报告指出,用氙气CT进行组织血流(TBF)定量分析可有效预测胰腺癌对抗癌药物的治疗反应。本研究的目的是评估用氙气CT计算的胰腺肿瘤TBF与灌注CT计算的TBF之间的相关性,以评估灌注CT是否可以替代氙气CT。
纳入9例经病理证实的胰腺肿瘤患者,这些患者均接受了氙气CT和灌注CT检查。
灌注CT测量的胰腺肿瘤定量TBF范围为22.1至196.2 ml/min/100 g(均值±标准差,52.6±54.8 ml/min/100 g)。相比之下,氙气CT获得的TBF范围为10.3至173.6 ml/min/100 g(均值±标准差,47.4±49.4 ml/min/100 g)。氙气CT和灌注CT之间存在良好的线性相关性(y = 0.8537x + 2.48,R2 = 0.895:p <0.05)。
氙气CT和灌注CT技术测量的胰腺肿瘤TBF显示出密切的线性相关性。我们可以预期,基于去卷积算法的灌注CT可能会替代氙气CT来预测胰腺癌用抗癌药物治疗的效果。